AFM
CLSD

Anson Funds Management’s Clearside Biomedical CLSD Stock Holding History

Anson Funds Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,559
Closed -$250K – 34
2018
Q4 		$250K Buy
+15,559
New +$730K 0.15% 37

Other funds holding CLSD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Anson Funds Management's CLSD Position: Q1 2019 in Review

Anson Funds Management sold out of Clearside Biomedical (CLSD) in Q1 2019, closing a stake of 15,559 shares — an estimated $250K sold.

Anson Funds Management first reported a position in CLSD in Q4 2018 and held it in 1 quarter. The position peaked at $250K in Q4 2018. 57 funds tracked by Wall St. Rank hold CLSD as of Q1 2019.

  • Anson Funds Management reported no remaining Clearside Biomedical position as of Q1 2019 after selling out during the quarter.
  • Anson Funds Management sold 15,559 Clearside Biomedical shares in Q1 2019, an estimated $250K.
  • Anson Funds Management first reported a position in Clearside Biomedical in Q4 2018 and held it in 1 quarter.
  • Anson Funds Management's Clearside Biomedical position peaked at $250K in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.